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Choriocarcinoma is a highly malignant tumour which originates from the developing 
trophoblastic tissue, most commonly following molar pregnancy. It is a potentially fatal 
disease, but current management protocols have changed the prognosis as highly 
favourable. 
The aim of the study was to analyze the ways of establishing the diagnosis, 
methods and results of treatment of choriocarcinoma in our institute. 
The study was conducted as a retrospective analysis of the eight-year period, from 
2000 to 2008. The obtained data were collected from medical charts with 
choriocarcinoma treated in our institute. 
In the eight-year period, eight cases of choriocarcinoma were registered. In one 
(12.5%) case choriocarcinoma developed after molar pregnancy, whereas in six (75%) 
cases the antecedent pregnancy resulted in a spontaneous abortion. In one patient the 
diagnosis was made after hysterectomy. Particular chemotherapeutic protocol was 
introduced to each patient. All patient survived. 
Prognosis of gestational choriocarcinoma is favourable provided the appropriate 
therapy is administered early in the course of disease. Provision of free medical care 
should be considered for these patients to save their lives. Acta Medica Medianae 
2012;51(2):11-14. 
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Introduction 
 
Gestational choriocarcinoma is a relatively 
rare and highly malignant variant of gestational 
trophoblastic disease. Although choriocarcinoma 
might be preceded by any gestational event, 
hydatidiform mole is the most common precursor 
(1). It is a potentially fatal disease, but availability 
of different diagnostic aids like radiology, serum 
human chorionic gonadotrophin (HCG) and unique 
sensitivity of tumour to chemotherapy has turned 
the prognosis highly favourable. It is one of the 
rare human malignancies that are highly curable 
even with wide spread metastasis. Prognosis of 
gestational choriocarcinoma largely depends upon 
early diagnosis of the disease, comprehensive meta-
static workup, selection of appropriate regimen of 
chemotherapy from outset and carefully planned 
follow up (2). 
Throughout the world, the incidence rates for 
choriocarcinoma differ widely. In Europe and North 
America, choriocarcinomas are reported to affect 
one in every 30.000-40.000 pregnancies, and one 
in 40 molar pregnancies, whereas in Southeast 
Asia, rates as high as one in every 500-3000 
pregnancies have been reported (3). These regional 
variations have been reported with many 
speculative factors as ethnic origin, blood group, 
age, parity, diet and nutrition, contraception, socio-
economic status, immunologic factors and genetic 
constitution (4). 
The aim of the paper was to analyze the 
ways of establishing the diagnosis, methods and 
results of treatment of choriocarcinoma in our 
institute. 
The study was conducted as a retrospective 
analysis of the eight-year period, from January 
2000 to October 2008, involving all patients with 
gestational choriocarcinoma presenting to the 
Institute of Gynaecology and Obstetrics, Clinical 
Centre of Serbia. On admission, a detailed history 
was obtained from each patient and thorough 
clinical examination was performed including 
general, systemic and pelvic examinations. Diagnosis 
of choriocarcinoma was mainly based on clinical 
course of the disease (history, abnormal vaginal 
bleeding, adnexal masses) and elevated levels of 
serum b-HCG. Evaluation of metastatic disease was 
done by thorough clinical examination and set of 
investigations including chest radio-graphy and 
ultrasound scan of abdomen and pelvis. There was 
no need for computed tomography. Patients were 
assigned low, medium and high risk groups 
according to the prognostic scoring system 
suggested by WHO in 1983 (Table 1).  Prognosis of gestational choriocarcinoma – 8 -year experience                                                                       Biljana Lazović et al. 
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Table 1. WHO Scoring System based on prognostic factors 
 
Score 
Prognostic Factors 
0 1 2 4 
Age (years)  <39  >39     
Antecedent Pregnancy 
Hydatidiform 
Mole 
Abortion Term  — 
Interval* 4  4–6  7–12  12 
hCG (IU/l)  <10
3 10
3–10
4 10
4–10
5 >10
5 
Largest tumour including 
uterine tumours 
—  3–5 Cm  >5 Cm  — 
Site of metastases  — 
Spleen 
Kidney 
GIT, Liver  Brain 
Number of metastases 
identified 
— 1–4  4–8  >8 
Prior Chemo 
therapy 
—  —  Single Drug  Two or more 
 
The total score for a patient is obtained by adding the individual score for each prognostic factor 
Total score: ≤4=low, 5–7= middle risk, ≥8= high risk 
*time interval (months) between end of antecedent pregnancy and start of chemotherapy 
 
Patients were managed in consultation with 
board for gestational trophoblastic disease. All 
patients were put on particular chemotherapeutic 
protocol according to risk score and prognostic 
factors. These protocols include Methotrexate (MTX), 
multiagens regime that consists of Metotrexate, 
Aktinomicina-D and Ciklofosfamid (MAC), and EMA-
CO protocol (composed of: Etopozyd, Metotrexate 
with folic acid, Aktinomycina-D, Cyklofosfamida and 
Vincristin). Therapy was monitored by serum 
concentration of b-HCG, which was estimated 
fortnightly. Chemotherapy was given cyclically 
until complete remission was attained. Patients 
were vigilantly observed for adverse effects of 
chemotherapy (vomiting, diarrhoea, liver function, 
bone marrow depression and alopecia) and 
supportive treatment was given. Radiotherapy was 
used only to treat the complications like vaginal 
haemorrhage. 
 
Results 
 
During the eight-year period there were eight 
patients suffering from choriocarcinoma. Epidemio-
logical features are given in Table 2. All patients 
survived. 
Table 3 shows the applied chemotherapeutic 
protocol for each patient. 
 
Discussion 
 
Out of eight patients, seven were multiparous 
and in only one patient the first pregnancy resulted 
in choriocarcinoma. Spontaneous abortion preceded 
choriocarcinoma in five patients (62.5%), while in 
two patients it was vaginal bleeding. Antecedent 
pregnancy was hydatidiform mole in one patient 
(12.5%). In the oldest patient in this group (48 
years old, with the history of two term deliveries 
and seven spontaneuos abortions), choriocarci-
noma was diagnosed after complete hysterectomy. 
Table 2. Baseline characteristic of patients with 
choriocarcinoma 
 
Age 
(years) 
Antecedent 
pregnancy and 
chemotherapy 
(months) 
Risk 
category 
Metastases 
48 13  middle  lung 
27 6 high  no 
29 5 high  lung 
27 8 high  no 
30 9  middle  lung 
32 4  low  no 
18 6 high  no 
29 5  middle  no 
 
Table 3. Chemotherapeutic protocol 
 
Age 
(years) 
Protocol 
Number of 
cycles of 
chemotherapy 
Complications of 
chemotherapy 
48 MTX,  MAC  3 
nausea, 
vomiting 
27 MAC  1 
nausea, 
vomiting 
29 
EMACO, 
MAC 
2 
rash, nausea, 
vomiting 
27 
EMACO, 
MTX, MAC 
3 
vomiting, 
nausea, alopecia 
30 
EMACO, 
MAC 
1 
nausea, 
vomiting 
32 MTX  1 
nausea, 
vomiting 
18 MTX  3 
fever, rash, 
vomiting, 
nausea 
29 MAC  1  nausea Acta Medica Medianae 2012, Vol.51(2)                                            Prognosis of gestational choriocarcinoma – 8 -year experience 
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Also, she had lung metastases and the longest 
period from the end of antecedent pregnancy and 
onset of chemotherapy (13 months). Knowledge of 
antecedent pregnancy is important because prog-
nosis depends upon it. Gestational trophoblastic 
disease most commonly follows molar pregnancy 
and may also occur following normal or ectopic 
pregnancies and spontaneous or therapeutic 
abortion (5). The incidence of choriocarcinoma after 
complete hydatiform mole is about 1000 times 
greater than after a normal pregnancy (6). Chorio-
carcinoma is suspected when there is persistent or 
irregular uterine haemorrhage, following abortion or 
hydatiform mole. Rapid growth and haemorrhage 
make the tumor a medical emergency.  
Majority  of  cases of choriocarcinoma occur  
in women aged less than  35 years of age (7). In 
our researh, the mean age was 30 years – the 
youngest was 18, the oldest 48 years old. Histe-
rectomy was performed in only one patient, after 
which choriocarcinoma was diagnosed.  
Patients were categorized in three groups as 
low, medium and high risk. The largest number 
(50%) belonged to group with a high risk score, 
than middle (37.5%) and one patient had low risk 
score. 
The b-HCG level was estimated prior to and 
during chemotherapy. On admission, levels of b-
HCG varied from 918 to 190000 IU/L. Average time 
of falling in b-HCG level after chemotherapy was 68 
days. 
Time interval between end of antecedent 
pregnancy and onset of chemotherapy was recorded. 
It varied from 4 to 13 months, on average 7 months. 
Time interval is a crucial factor influencing the 
prognosis. If it is shorter and chemotherapy 
starts sooner, the prognosis is better. 
As trophoblastic tissue has a tendency for 
hematogenous dissemination, the lungs and their 
vascular system are usually involved by pulmonary 
metastasis (85% in related choriocarcinoma), tumor 
emboli with or without lung infarct. Other organs 
where metastasis may occur are the CNS, uterus, 
vagina, liver, and spleen (8). Pulmonary metastasis 
in GTD usually has a good prognosis compared to 
brain metastasis. The mortality rate of patients with 
pulmonary metastasis was found to be 8%. These 
metastases tend to disappear rapidly in response to 
drugs, radiotherapy, or surgery (9). In our research, 
lung metastases were present in three patients. 
They responded well to chemotherapy. 
Chemotherapy was administered to all 
patients. Radiotherapy was not used as a primary 
treatment, but it was given to two patients who 
developed massive vaginal haemorrhage. No 
patient was treated with surgical resection. The 
number of cycles of chemotherapy did not exceed 
three cycles. 
All the patients had nausea and vomiting, 
one developed alopecia, two patients had rash and 
one had fever. No one had bone marrow 
depression. No other adverse effects were seen.  
It is apparent from the above study that all 
patients with choriocarcinoma are potentially 
curable provided that the appropriate therapy is 
given early enough in the course of the disease. In 
our study 100% patients attained complete 
remission and they survived without any morbidity 
during the two-year follow up period. There were 
no patients who did not respond to chemotherapy. 
 
Conclusion 
 
As a result of modern diagnostic and thera-
peutic techniques, nearly 100 percent of patients 
with GTD can be cured of a disease that recently 
had a high death rate. To achieve this, skillful 
mixing of chemotherapy, surgery, and irradiation, 
as well as supportive therapy, are necessary. 
Complete remission can be obtained in majority 
of patients by administration of appropriate 
chemotherapy from the outset. Prognosis depends 
upon early diagnosis and management. Under-
standing and utilizing the HCG assay to monitor 
disease status is vital, because a rapid diagnosis 
and treatment may change dramatically their 
survival. With this approach, essentially all of 
these patients should survive, many to have 
successful future pregnancies. According to 
presented data, we can conclude that 
chemotherapeutic treatment is very efficient in the 
treatment of choriocarcinoma. 
Continued awareness and education is 
required, so that choriocarcinoma developing after 
molar or non-molar pregnancy is detected as early 
as possible, thereby reducing the choriocarcinoma 
mortality rate. 
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PROGNOZA GESTACIJSKOG HORIOKARCINOMA 
 – OSMOGODIŠNJE ISKUSTVO 
 
Biljana Lazović i Vera Milenković 
 
 
Horiokarcinom predstavlja maligni tumor trofoblastnog tkiva. Najčešće nastaje 
nakon molarne trudnoće. Nekada je horiokarcinom bio fatalno oboljenje, a danas je 
najbolje lečeni ginekološki malignitet zahvaljujući savremenim protokolima. 
Cilj rada bio je analiziranje načina postavljanja dijagnoze, metoda i rezultate 
lečenja horiokarcinoma u Institutu za ginekologiju i akušerstvo. Urađena je 
retrospektivna analiza svih bolesnica obolelih od horiokarcinoma u osmogodišnjem 
periodu (2000.-2008.). 
U periodu praćenja registrovano je ukupno 8 žena obolelih od horiokarcinoma. 
Kod jedne bolesnice (12,5% slučajeva) horiokarcinom se razvio nakon molarne 
trudnoće, dok je kod 6 (75%) slučajeva prethodio spontani abortus. Kod jedne 
bolesnice dijagnoza je postavljena nakon histerektomije. Sve bolesnice su uspešno 
izlečene, nije bilo smrtnih ishoda. 
Ukoliko se dijagnoza i lečenje postavi i započne u ranijem stadijumu bolesti, 
može se očekivati povoljan ishod.  Acta Medica Medianae 2012;51(2):11-14. 
 
Ključne reči: horiokarcinom, lečenje, hemoterapija 
 